Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $37.22 USD
Change Today -1.40 / -3.63%
Volume 400.3K
IPXL On Other Exchanges
As of 3:31 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (IPXL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $52.10
52 Week Low
10/15/14 - $26.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

impax laboratories inc (IPXL) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (IPXL) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

1,061 Employees
Last Reported Date: 02/26/15
Founded in 1993

impax laboratories inc (IPXL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $552.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $446.2K
President of Impax Pharmaceuticals
Total Annual Compensation: $515.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $484.2K
Senior Vice President of Technical Operations
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

impax laboratories inc (IPXL) Key Developments

Impax Laboratories Inc. Amends the Amended and Restated Bylaws

On and effective October 7, 2015, the Board amended the amended and restated bylaws of Impax Laboratories Inc., as amended (the Bylaws). The amendment to the Bylaws (Amendment No. 3) amends Article III, Section 14 of the Bylaws to increase the maximum number of directors authorized to serve on the Board from eight to nine.

Impax Laboratories, Inc. Appoints Janet S. Vergis to its Board of Directors

Impax Laboratories Inc. announced that Janet S. Vergis has been appointed to the company's Board of Directors effective as of October 7, 2015. Ms. Vergis currently serves as an executive advisor to private equity firms and has more than twenty-seven years of pharmaceutical experience.

U.S. Food and Drug Administration Announces Approval for Impax Laboratories Inc.'s Generic Version of DIABETA (Glyburide) Tablets

Impax Laboratories Inc. announced that the U.S. Food and Drug Administration has approved its generic version of glyburide tablets 1.25 mg, 2.5 mg, and 5 mg. The company is preparing for commercialization of this product through Impax's generic division.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $37.22 USD -1.40

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $27.56 USD -1.65
BTG PLC 572.00 GBp +12.00
Lannett Co Inc $44.80 USD -1.55
Prestige Brands Holdings Inc $47.61 USD -1.15
Medicines Co/The $33.95 USD -1.06
View Industry Companies

Industry Analysis


Industry Average

Valuation IPXL Industry Range
Price/Earnings 100.0x
Price/Sales 4.1x
Price/Book 2.7x
Price/Cash Flow 364.4x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at